Anticoagulant and Antiplatelet Drug Molecules

Anticoagulant and antiplatelet drug molecules represent two classes of medications used to prevent and treat thrombotic disorders. Anticoagulant drugs work by inhibiting key steps in the coagulation cascade, reducing formation of fibrin-rich clots, and are vital for managing deep vein thrombosis, pulmonary embolism, and atrial fibrillation. Antiplatelet drugs interfere with platelet activation and aggregation, targeting enzymes and receptors such as cyclooxygenase (COX), P2Y12, and glycoprotein IIb/IIIa, primarily to prevent arterial clots responsible for heart attacks and strokes. Because this entry refers to a group/class rather than a specific target, it is not suitable for structured molecular data extraction.

Other names

Antithrombotic drugsBlood thinners

Anticoagulant drugs: Inhibit various components of the coagulation cascade, e.g., Factor Xa (apixaban, rivaroxaban), thrombin (heparin), synthesis of vitamin K-dependent factors (warfarin). Antiplatelet drugs: Inhibit platelet activation/aggregation via: Irreversible cyclooxygenase inhibition (aspirin), P2Y12 receptor antagonism (clopidogrel, prasugrel, ticagrelor, cangrelor), Glycoprotein IIb/IIIa receptor blockade (abciximab, eptifibatide, tirofiban), Phosphodiesterase inhibition (dipyridamole, cilostazol).